Yale Comprehensive Cancer Center Support Grant

耶鲁大学综合癌症中心支持补助金

• 批准号: 9128586
• 负责人: CHARLES S FUCHS
• 金额: $ 260万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-07-01 至 2018-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9128586
• 关键词: Aftercare; Basic Science; Biometry; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Hospital; Cancer Immunology Science; Cancer Patient; Caring; Cesium; Clinical; Clinical Sciences; Clinical Trials; Comprehensive Cancer Center; Development; Developmental Therapeutics Program; Education; Epidemiology; Etiology; Evaluation; Flow Cytometry; Fostering; Funding; Goals; Growth; Hospitals; Institutes; Instruction; Leadership; Malignant Neoplasms; Mission; Molecular; Molecular Virology; Morbidity - disease rate; Pain; Pathology; Patient Care; Patients; Population; Population Sciences; Prevention; Process; Publishing; Radiation therapy; Radiobiology; Recruitment Activity; Research; Research Personnel; Resource Sharing; Scientist; Services; Signal Transduction; Strategic Planning; Therapeutic Clinical Trial; Tissues; Training; Translating; Translational Research; United States; Yale Cancer Center; anticancer research; cancer genetics; cancer genomics; cancer prevention; clinical care; end of life; genome analysis; improved; member; mortality; multidisciplinary; next generation; palliative; patient oriented; programs; screening; survivorship; tumor immunology

DESCRIPTION (provided by applicant): The core mission of the Yale Cancer Center is to reduce suffering from cancer by being a global leader in cancer research, care and education. Designated as a Comprehensive Cancer Center in 1974, the past five years have been a period of significant growth and restructuring. Dr. Thomas Lynch became the 6th Director of the YCC in April 2009 and recruited more than 80 new basic, population, translational and clinical scientists. In addition to appointing a new Deputy Director, Dr. Daniel DiMaio, Senior Leadership and cancer Center Administration was completely redesigned. For this submission 6 of 7 Research Programs are under new leadership. During the most recent funding period, the YCCs 260 members published 2751 articles, (21% intra-programmatic and 14% inter-programmatic) and hold $93M in total cancer funding (including $29M from NCI). Accrual to therapeutic clinical trials more than doubled over the past year. Driven by remarkable institutional support, significant expansion during the prior funding period included building the $450M Smilow Cancer Hospital, opening 7 regional Care Centers in Southern CT and acquiring the former Hospital St. Raphael to create the nation's 4th largest hospital. This clinical care expansion was matched by establishing the Yale Cancer Biology Institute at Yale's West Campus. A detailed strategic planning process has begun with a resultant strong emphasis on optimizing our research programs and shared resources and investing in translational research, cancer genetics, and tumor immunology. This 5-year request is to support an organizational framework that promotes and fosters basic and translational cancer research. The 7 Research Programs include: Cancer Genetics and Genomics, Cancer Immunology, Cancer Prevention and Control, Developmental Therapeutics, Molecular Virology, Radiobiology and Radiotherapy and Signal Transduction. Support is requested for 8 Shared Resources including Yale Center for Genome Analysis, Flow Cytometry, Yale Pathology Tissue Services, Cesium Irradiator, Rapid Case Ascertainment, Yale Center for Molecular Discovery, Biostatistics and the Clinical Trials Office. To support center goals and objectives support for Senior Leadership, Planning and Evaluation, Administration, and Developmental Funds is also requested.

描述（由申请人提供）：耶鲁大学癌症中心的核心使命是通过成为癌症研究、护理和教育领域的全球领导者来减少癌症痛苦。 1974 年被指定为综合癌症中心，过去五年是显着增长和重组的时期。 Thomas Lynch 博士于 2009 年 4 月成为 YCC 第六任主任，并招募了 80 多名新的基础、人口、转化和临床科学家。 除了任命新的副主任 Daniel DiMaio 博士外，高级领导层和癌症中心行政管理也进行了彻底重新设计。本次提交的 7 个研究项目中有 6 个由新领导领导。在最近的资助期内，YCC 的 260 名成员发表了 2751 篇文章（21% 为项目内文章，14% 为项目间文章），并持有总计 9300 万美元的癌症资金（包括来自 NCI 的 2900 万美元）。过去一年，治疗性临床试验的增量增加了一倍多。在出色的机构支持的推动下，上一资助期间的重大扩张包括建造价值 4.5 亿美元的 Smilow 癌症医院、在康涅狄格州南部开设 7 个区域护理中心以及收购前圣拉斐尔医院以创建全国第四大医院。与此同时，在耶鲁大学西校区建立了耶鲁癌症生物学研究所，以配合临床护理的扩展。详细的战略规划流程已经开始，重点是优化我们的研究项目和共享资源，并投资于转化研究、癌症遗传学和肿瘤免疫学。这项为期五年的请求是为了支持一个促进和促进基础和转化癌症研究的组织框架。 7个研究项目包括：癌症遗传学和基因组学、癌症免疫学、癌症预防和控制、发育治疗学、分子病毒学、放射生物学和放射治疗和信号转导。请求支持 8 个共享资源，包括耶鲁大学基因组分析中心、流式细胞术、耶鲁大学病理组织服务、铯辐照器、快速病例查明、耶鲁大学分子发现中心、生物统计学和临床​​试验办公室。为了支持中心的目标和目的，还要求为高级领导、规划和评估、管理和发展基金提供支持。